Indirect cholinergic system support

Indirect cholinergic system support refers to a therapeutic strategy aimed at increasing the concentration or activity of endogenous acetylcholine (ACh) without directly binding to nicotinic or muscarinic receptors. This approach is primarily executed through the inhibition of acetylcholinesterase (AChE), the enzyme responsible for the rapid degradation of ACh in the synaptic cleft and neuromuscular junction (NIH, 2022). By preventing this breakdown, drugs such as donepezil and pyridostigmine prolong the action of endogenous ACh, thereby enhancing neurotransmission in both the central and peripheral nervous systems. This mechanism is a standard of care for managing cognitive decline in Alzheimer's disease and restoring muscle strength in myasthenia gravis (PubMed, 2021). Beyond enzyme inhibition, this strategy also encompasses the use of high-bioavailability choline donors, which serve as precursors to ensure adequate neurotransmitter synthesis in depleted states. While effective, indirect support can lead to systemic cholinergic overstimulation, often characterized by gastrointestinal and cardiovascular side effects.

Other names

Cholinergic enhancementIndirect cholinergic modulationPro-cholinergic therapyCholinomimetic support

Enhancement of cholinergic signaling primarily through the reversible or irreversible inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), which prevents the hydrolysis of acetylcholine in the synaptic cleft (StatPearls, 2023). Additionally, it involves the administration of choline precursors (e.g., Citicoline) to increase the biosynthetic substrate available for acetylcholine production (Nutrients, 2020).